• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CT1
Click for more information
0.00% 0.2¢

CONSTELLATION TECHNOLOGIES LIMITED - Announcements

Market Cap $1.474M  ! watchlist Created with Sketch. Add to my watchlist

Constellation Technologies Limited is an Australia-based Internet of things (IoT) and... Constellation Technologies Limited is an Australia-based Internet of things (IoT) and digital solutions company. The Company is focused on offering solutions to market, which leverage cloud, IoT, edge-computing sensors, big data, analytics, machine learning (ML), artificial intelligence (AI) and other advanced technologies. The Company through Callisto offers a range of solutions designed to address various industry needs. These solutions include Food Safety & Compliance, Drugs & Medicine Monitoring, Cold Chain Logistics, and Asset Management. Its Gen3 IoT product line offers IoT devices that can capture critical data points across a range of applications, providing its customers with reliable and flexible solutions that support multiple communication networks and sensor customization. Its MeridianCT is a cloud-based software platform and mobile application, which enables users to have an end-to-end IoT data solution to connect, monitor and visualize their data. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CT1 Agenix recoveries in China continuePRICE SENSITIVE29/09/10
CT1 Agenix surrenders final Queensland lease,PRICE SENSITIVE20/09/10
CT1 Change in substantial holding17/09/10
CT1 Change in substantial holding16/09/10
CT1 Agenix's Hepatitis B Drug Passes its First HurdlePRICE SENSITIVE15/09/10
CT1 Agreement reached on Hepatitis B drug in China08/09/10
CT1 Reinstatement to official quotation - 10/09/10PRICE SENSITIVE08/09/10
CT1 ASX Circular - Agenix Ltd - Reinstatement08/09/10
CT1 Request for Reinstatement to Official Quotation08/09/10
CT1 Appendix 3B03/09/10
CT1 FY2010 Annual Report to shareholders31/08/10
CT1 Preliminary Final Report31/08/10
CT1 Appendix 3B30/08/10
CT1 Change in substantial holding27/08/10
CT1 Appendix 3B27/08/10
CT1 Results of FY2009 AGM27/08/10
CT1 Executive Chairman's Address to FY2009 AGM27/08/10
CT1 Becoming a substantial holder13/08/10
CT1 Notice of Annual General Meeting/Proxy Form28/07/10
CT1 Recoveries continue in China01/07/10
CT1 Update on path back to trading shares on ASX08/06/10
CT1 Preliminary Final Report04/06/10
CT1 Half Yearly Report and Accounts04/06/10
CT1 Annual Report to shareholders04/06/10
CT1 Preliminary Final Report04/06/10
CT1 Preliminary Final Report04/06/10
CT1 Half Year Accounts04/06/10
CT1 Recoveries in China Continue08/04/10
CT1 Update on Company Operations30/03/10
CT1 Agenix secures $5m funding facility25/03/10
CT1 Conviction of former CEO Neil Leggett for fraud against AGX19/02/10
CT1 Recoveries in China Continue13/01/10
CT1 Final Director's Interest Notice04/01/10
CT1 Executive Chairman Appointment04/01/10
CT1 Change in substantial holding16/12/09
CT1 Chinese parties fail to complete Deed of Variation15/12/09
CT1 Appendix 3B15/12/09
CT1 Change in substantial holding04/12/09
CT1 Change in substantial holding04/12/09
CT1 Change in substantial holding04/12/09
CT1 Convertible Notes Mature and Convert to Ordinary Shares02/12/09
CT1 Variation to Final Settlement Deed01/12/09
CT1 Amended Appendix 3B01/12/09
CT1 Change of Director's Interest Notice30/11/09
CT1 Change of Director's Interest Notice30/11/09
CT1 Appendix 3B30/11/09
CT1 Final Director's Interest Notice02/11/09
CT1 Results of FY2008 AGM30/10/09
CT1 FY2008 AGM Chairman's Address30/10/09
CT1 Chief Financial Officer Appointment05/10/09
CT1 FY2008 AGM Withdrawal Notice of Resolution 1101/10/09
CT1 FY2008 AGM Proxy Form01/10/09
CT1 Notice of FY2008 AGM and Explanatory Memorandum01/10/09
CT1 FY2008 Annual Financial Report24/09/09
CT1 Appendix 4E - FY2008 Preliminary Financial Report24/09/09
CT1 FY2008 Annual General Meeting24/09/09
CT1 Change of Registered Address07/09/09
CT1 Approval Date for Oct 2008 Convertible Note Issue Extended03/09/09
CT1 CEO Contract Not to be Renewed19/08/09
CT1 Notice of Instalments Received14/08/09
CT1 Agenix raises $1m with Convertible Note issue10/08/09
CT1 Notice of Instalments Received17/07/09
CT1 Update on Company Operations18/06/09
CT1 Notice of Instalments Received04/06/09
CT1 Correction on share value29/05/09
CT1 Warning regarding unsolicited share offers28/05/09
CT1 Notice of Instalments Received08/05/09
CT1 Binding Settlement Agreements Signed with Chinese Parties16/04/09
CT1 Update on Company Operations27/03/09
CT1 Update on Company Operations16/02/09
CT1 ThromboView Ready for Phase III Trials13/02/09
CT1 Lapse of Preliminary Settlement Deed05/01/09
CT1 Receipt of First Instalment17/12/08
CT1 Agenix settles Chinese acquisition issues09/12/08
CT1 Agenix recoveries in China continue
29/09/10PRICE SENSITIVE
CT1 Agenix surrenders final Queensland lease,
20/09/10PRICE SENSITIVE
CT1 Change in substantial holding
17/09/10
CT1 Change in substantial holding
16/09/10
CT1 Agenix's Hepatitis B Drug Passes its First Hurdle
15/09/10PRICE SENSITIVE
CT1 Agreement reached on Hepatitis B drug in China
08/09/10
CT1 Reinstatement to official quotation - 10/09/10
08/09/10PRICE SENSITIVE
CT1 ASX Circular - Agenix Ltd - Reinstatement
08/09/10
CT1 Request for Reinstatement to Official Quotation
08/09/10
CT1 Appendix 3B
03/09/10
CT1 FY2010 Annual Report to shareholders
31/08/10
CT1 Preliminary Final Report
31/08/10
CT1 Appendix 3B
30/08/10
CT1 Change in substantial holding
27/08/10
CT1 Appendix 3B
27/08/10
CT1 Results of FY2009 AGM
27/08/10
CT1 Executive Chairman's Address to FY2009 AGM
27/08/10
CT1 Becoming a substantial holder
13/08/10
CT1 Notice of Annual General Meeting/Proxy Form
28/07/10
CT1 Recoveries continue in China
01/07/10
CT1 Update on path back to trading shares on ASX
08/06/10
CT1 Preliminary Final Report
04/06/10
CT1 Half Yearly Report and Accounts
04/06/10
CT1 Annual Report to shareholders
04/06/10
CT1 Preliminary Final Report
04/06/10
CT1 Preliminary Final Report
04/06/10
CT1 Half Year Accounts
04/06/10
CT1 Recoveries in China Continue
08/04/10
CT1 Update on Company Operations
30/03/10
CT1 Agenix secures $5m funding facility
25/03/10
CT1 Conviction of former CEO Neil Leggett for fraud against AGX
19/02/10
CT1 Recoveries in China Continue
13/01/10
CT1 Final Director's Interest Notice
04/01/10
CT1 Executive Chairman Appointment
04/01/10
CT1 Change in substantial holding
16/12/09
CT1 Chinese parties fail to complete Deed of Variation
15/12/09
CT1 Appendix 3B
15/12/09
CT1 Change in substantial holding
04/12/09
CT1 Change in substantial holding
04/12/09
CT1 Change in substantial holding
04/12/09
CT1 Convertible Notes Mature and Convert to Ordinary Shares
02/12/09
CT1 Variation to Final Settlement Deed
01/12/09
CT1 Amended Appendix 3B
01/12/09
CT1 Change of Director's Interest Notice
30/11/09
CT1 Change of Director's Interest Notice
30/11/09
CT1 Appendix 3B
30/11/09
CT1 Final Director's Interest Notice
02/11/09
CT1 Results of FY2008 AGM
30/10/09
CT1 FY2008 AGM Chairman's Address
30/10/09
CT1 Chief Financial Officer Appointment
05/10/09
CT1 FY2008 AGM Withdrawal Notice of Resolution 11
01/10/09
CT1 FY2008 AGM Proxy Form
01/10/09
CT1 Notice of FY2008 AGM and Explanatory Memorandum
01/10/09
CT1 FY2008 Annual Financial Report
24/09/09
CT1 Appendix 4E - FY2008 Preliminary Financial Report
24/09/09
CT1 FY2008 Annual General Meeting
24/09/09
CT1 Change of Registered Address
07/09/09
CT1 Approval Date for Oct 2008 Convertible Note Issue Extended
03/09/09
CT1 CEO Contract Not to be Renewed
19/08/09
CT1 Notice of Instalments Received
14/08/09
CT1 Agenix raises $1m with Convertible Note issue
10/08/09
CT1 Notice of Instalments Received
17/07/09
CT1 Update on Company Operations
18/06/09
CT1 Notice of Instalments Received
04/06/09
CT1 Correction on share value
29/05/09
CT1 Warning regarding unsolicited share offers
28/05/09
CT1 Notice of Instalments Received
08/05/09
CT1 Binding Settlement Agreements Signed with Chinese Parties
16/04/09
CT1 Update on Company Operations
27/03/09
CT1 Update on Company Operations
16/02/09
CT1 ThromboView Ready for Phase III Trials
13/02/09
CT1 Lapse of Preliminary Settlement Deed
05/01/09
CT1 Receipt of First Instalment
17/12/08
CT1 Agenix settles Chinese acquisition issues
09/12/08
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $1.474M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $9.104K 4.552M

Buyers (Bids)

No. Vol. Price($)
32 23995490 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 222518 2
View Market Depth
Last trade - 12.55pm 22/11/2024 (20 minute delay) ?
CT1 (ASX) Chart

Top Stories

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.